James Love and James K. Glassman, Don’t Kill Competition for High-Tech Drugs, Roll Call, Sept. 9, 2009 [1].
KEI Statement on Eshoo/Barton amendment [2]
Some reporting
- James Love and James K. Glassman, Don’t Kill Competition for High-Tech Drugs, Roll Call, Sept. 9, 2009 [1].
- 20 July 2009. Ceci Connolly, Washington Post. “With Health Reform, Waxman Takes On Another Tall Order [3]“
- 20 July 2009. James Love, Knowledge Ecology Notes. “Howard Dean as a shill for BIO, on Biosimilars bill [4]“
- 20 July 2009. James Love, The Huffington Post. “Howard Dean — Now a Shill for BIO [5]“
- 17 July 2009. James Love, The Huffington Post. “Joe Trippi Admits He Works for BIO, While He Plugs BIO Bill in HuffPo [6]“
- 13 July 2009. Timothy Noah, Slate Magazine. “An Amgen Payoff? Why is Ted Kennedy being so nice to the biotech industry? [7]“
Background Documents and Links
- Essential Action’s page on Biogenerics [8]
- 10 June 2009. FTC press release. FTC Releases Report on “Follow-on Biologic Drug Competition” [9]
June 2009. Federal Trade Commission Report. Emerging Health Care Issues: Follow-on Biologic Drug Competitio [10]
- 18 June 2009. Maureen Martino, FierceBiotech. “Biologics will dominate in 2014 [11] “
- 20 July 2009. Letter [12] to Members of Congress from Public Health Groups and State Legislators to Oppose Biogenerics Proposal.
- 16 July 2009. KEI statement [13] urging Congress to reject the 12-14.5 year monopoly for biologic products provided in H.R.1548.
- 14 July 2009. Letter [14] from the American Medical Student Association, Essential Action, and Universities Allied for Essential Medicines to the American Association of Universities.
- 22 April 2009. Senate [15] and House [16] versions of the letter from Consumer, Patient and Public Health Groups and Unions endorsing the bipartisan Promoting Innovation and Access to Life-Saving Medicine Act (S. 726).